Научно-практический журнал
«Клиническая физиология кровообращения»

Главный редактор

Лео Антонович Бокерия, доктор медицинских наук, профессор, академик РАН и РАМН, президент ФГБУ «НМИЦ ССХ им. А.Н. Бакулева» МЗ РФ


Фибрилляция предсердий у онкологических пациентов

Авторы: Акилджонов Ф.Р., Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф.

Организация:
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева» Минздрава России, Москва, Российская Федерация

Для корреспонденции: Сведения доступны для зарегистрированных пользователей.

Раздел: Обзоры

DOI: https://doi.org/I: 10.24022/1814-6910-2022-19-1-16-24

УДК: 616.12-008.313.2:616-006

Библиографическая ссылка: Клиническая физиология кровообращения. 2022; 1 (19): 16-24

Цитировать как: Акилджонов Ф.Р., Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф. . Фибрилляция предсердий у онкологических пациентов. Клиническая физиология кровообращения. 2022; 1 (19): 16-24. DOI: I: 10.24022/1814-6910-2022-19-1-16-24

Ключевые слова: фибрилляция предсердий, онкология, биомаркеры

Поступила / Принята к печати:  21.10.2021 / 23.11.2021

Полнотекстовая версия:
Оформить подписку 🔒

Аннотация

Фибрилляция предсердий (ФП) – наиболее распространенная устойчивая аритмия, и ее возникновение связано со значительным увеличением числа случаев госпитализации и смертности от сердечнососудистых осложнений. Профилактика ишемического инсульта у пациентов с онкологическими заболеваниями и ФП обычно проводится так же, как у пациентов, не страдающих онкопатологией, и рандомизированные исследования не выполнялись. Однако такие больные представляют собой особую категорию пациентов, при их лечении важно обращать внимание на стадию рака, прогноз и возможное взаимодействие с фоновой химиотерапией. У пациентов со злокачественными новообразованиями и ФП требуются мультидисциплинарный подход совместно с кардиологами и онкологами, тщательное планирование антикоагулянтной терапии и инициация антиаритмической терапии. Дальнейшие исследования позволят разработать новые инструменты для улучшения стратификации риска у пациентов с ФП и онкологическими заболеваниями, определить преимущества при выборе оптимальных стратегий антикоагулянтного лечения, как для профилактики тромбоэмболических осложнений, так и для стратификации риска развития крупных кровотечений.

Литература

  1. Бокерия Л.А., Шенгелия Л.Д. Лечение фибрилляции предсердий. Часть I. Долгий путь к «золотому стандарту». Анналы аритмологии. 2014; 11 (2): 64–76. DOI: 10.15275/annaritmol.2014.2.1
  2. Бокерия Л.А., Базаев В.А., Филатов А.Г., Меликулов А.Х., Висков Р.В., Грицай А.Н. Изолированная форма фибрилляции предсердий. Анналы аритмологии. 2006; 3 (2): 39–47.
  3. Akamatsu K., Ito T., Ozeki M., Miyamura M., Sohmiya K., Hoshiga M. Left atrial spontaneous echo contrast occurring in patients with low CHADS2 or CHA2DS2-VASc scores. Cardiovasc. Ultrasound. 2020; 18 (1): 31. DOI: 10.1186/s12947-020-00213-2
  4. Wang C., Wu V., Tu H., Huang Y., Chen Sh., Chu P. et al. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. J. Thromb. Thrombolysis. 2021. DOI: 10.1007/s11239-021-02570-9
  5. Lateef N., Kapoor V., Ahsan M. Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. J. Community Hosp. Intern. Med. Perspect. 2020; 10 (2): 127–32. DOI: 10.1080/20009666.2020.1726571
  6. O’Neal W.T., Lakoski S.G., Qureshi W. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am. J. Cardiol. 2015; 115 (8): 1090–4. DOI: 10.1016/j.amjcard.2015.01.540
  7. Garcia S., Canoniero M., Sattiraju S. Atrial fibrillation after lung transplantation: incidence, predictors and long-term implications. J. Atr. Fibrillation. 2011; 4 (3): 363. DOI: 10.4022/jafib.363
  8. Hsu J., Huang C., Chuang S. Long term outcome of postoperative atrial fibrillation after cardiac surgery – a propensity score-matched cohort analysis. Front Cardiovasc. Med. 2021; 8: 650147. DOI: 10.3389/fcvm.2021.650147
  9. Gong J., Wang X., Liu Z. Risk factors and survival analysis of arrhythmia following lung cancer surgery: a retrospective study. J. Thorac. Dis. 2021; 13 (2): 847–60. DOI: 10.21037/jtd-20-2740
  10. Asnani A., Manning A., Mansour M., Ruskin J., Hochberg E., Ptaszek L. Management of atrial fibrillation in patients taking targeted cancer therapies. Cardiooncology. 2017; 3: 2. DOI: 10.1186/s40959-017-0021-y
  11. Kattelus H., KesКniemi Y., Huikuri H., Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). PLoS One. 2018; 13 (10): e0205454. DOI: 10.1371/journal.pone.0205454
  12. Tamura Y., Sawabata N., Susaki Y., Nakamura T., Taniguchi S. Effect of cardiac expansion on postsurgical pulmonary resection recovery. In Vivo. 2019; 33 (6): 1977–84. DOI: 10.21873/invivo.11693
  13. Kalra R., Parcha V., Patel N. Implications of atrial fibrillation among patients with atherosclerotic cardiovascular disease undergoing noncardiac surgery. Am. J. Cardiol. 2020; 125 (12): 1836–44. DOI: 10.1016/j.amjcard.2020.03.028
  14. Hung C.S., Chang C.H., Lin J.W., Ho Y.L., Chen M.F. The association between new onset atrial fibrillation and incident cancer – a nationwide cohort study. PLoS One. 2018; 13 (6): e0199901. DOI: 10.1371/journal.pone.0199901
  15. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 2020; 17 (8): 474–502. DOI: 10.1038/s41569-020- 0348-1
  16. Ren M., Yao Y., Yue X., Ning Y., Yang Y. Atrial cardiomyopathy and atrial fibrillation in cancer. Cardiol. Res. Pract. 2021; 2021: 6685951. DOI: 10.1155/2021/6685953
  17. Aboumsallem J.P., Moslehi J., de Boer R.A. Reverse cardio-oncology: cancer development in patients with cardiovascular disease. J. Am. Heart Assoc. 2020; 9 (2): e013754. DOI: 10.1161/JAHA.119.013754
  18. Zamorano J.L. Specific risk of atrial fibrillation and stroke in oncology patients. Eur. Heart J. 2016; 37 (36): 2747–8. DOI: 10.1093/eurheartj/ehw385
  19. Anderson J.L., Halperin J.L., Albert N.M. Management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 61 (18): 1935–44. DOI: 10.1016/j.jacc.2013.02.001
  20. Kaplan A., Joca H., Boyman L., Greiser M. Calcium signaling silencing in atrial fibrillation: implications for atrial sodium homeostasis. Int. J. Mol. Sci. 2021; 22 (19): 10513. DOI: 10.3390/ijms221910513
  21. Yang X., Li Y. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front. Physiol. 2017; 8: 600. DOI: 10.3389/fphys.2017.00600
  22. Samman Tahhan A., Sandesara P.B., Hayek S.S. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017; 14 (12): 1849–55. DOI: 10.1016/j.hrthm.2017.07.028
  23. Yang X., Li X., Yuan M. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018; 9: 1058. DOI: 10.3389/fphar.2018.01058
  24. Meessen J., Cardinale D., Ciceri F. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail. 2020; 7 (4): 1452–66. DOI: 10.1002/ehf2.12695
  25. Liu Y., Tan D., Shi L. Blueberry anthocyanins-enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLOS One. 2015; 10 (7): e0127813. DOI: 10.1371/journal. pone.0127813
  26. Li N., Brundel B. Inflammasomes and proteostasis novel molecular mechanisms associated with atrial fibrillation. Circ. Res. 2020; 127 (1): 73–90. DOI: 10.1161/CIRCRESAHA.119.316364
  27. Yuan M., Zhang Z., Tse G., Feng X., Korantzopoulos P., Letsas K.P. et al. Association of cancer and the risk of developing atrial fibrillation: a systematic review and meta-analysis. Cardiol. Res. Pract. 2019; 2019: 8985273. DOI: 10.1155/2019/8985273
  28. January C.T., Wann L.S., Calkins H. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140 (2): e125–e151. DOI: 10.1161/CIR.0000000000000665
  29. Citro R., Prota C., Resciniti E. Thrombotic risk in cancer patients: diagnosis and management of venous thromboembolism. J. Cardiovasc. Echogr. 2020; 30 (Suppl. 1): S38–S44. DOI: 10.4103/jcecho. jcecho_63_19
  30. Kim K., Lee Y.J., Kim T.H. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circ. J. 2018; 48 (5): 406–17. DOI: 10.4070/kcj.2017.0328
  31. Mosarla R.C., Vaduganathan M., Qamar A., Moslehi J., Piazza G., Giugliano R.P. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J. Am. Coll. Cardiol. 2019; 73 (11): 1336–49. DOI: 10.1016/j.jacc.2019.01.017
  32. Khan Y., Zaidi S.O., Razak B.S., Zaki M., Malik B.H. Use of new oral anticoagulants/direct oral anticoagulants in malignant patients. Cureus. 2020; 12 (2): e7007. DOI: 10.7759/cureus.7007
  33. Ma S., Mao Z., Wu Y. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell. Adh. Migr. 2020; 14 (1): 118–28. DOI: 10.1080/19336918.2020.1767489
  34. Horlocker T., Vandermeuelen E., Kopp S., Gogarten W., Leffert L., Benzon H. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg. Anesth. Pain. Med. 2018; 43 (3): 263–309. DOI: 10.1097/AAP.0000000000000763
  35. Chandrasekhar S., Fradley M.G. QT Interval prolongation associated with cytotoxic and targeted cancer therapeutics. Curr. Treat. Options. Oncol. 2019; 20 (7): 55. DOI: 10.1007/s11864-019-0657-y
  36. Bickford C., Agarwal R., Urbauer D., Durand J., Lenihan D. Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients. Am. J. Med. Sci. 2014; 347 (4): 277–81. DOI: 10.1097/MAJ.0b013e31828a7656
  37. Matta M., Gaita F., Anselmino M. Catheter ablation of atrial fibrillation in chronic heart failure: a contemporary review. J. Innov. Card. Rhythm. Manag. 2017; 8 (3): 2648–56. DOI: 10.19102/icrm.2017.080304
  38. Amar D., Zhang H., Tan K.S., Piening D., Rusch V.W., Jones D.R. A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: development and internal validation. J. Thorac. Cardiovasc. Surg. 2019; 157 (6): 2493–9.e1. DOI: 10.1016/j.jtcvs. 2019.01.075
  39. Fabiani I., Colombo A., Bacchiani G., Cipolla C., Cardinale D. Incidence, management, prevention and outcome of post-operative atrial fibrillation in thoracic surgical oncology. J. Clin. Med. 2019; 9 (1): 37. DOI: 10.3390/jcm9010037
  40. Semeraro G., Meroni C., Cipolla C., Cardinale D. Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel). 2021; 13 (16): 4012. DOI: 10.3390/cancers 13164012
  41. Tong C., Zhang Q., Liu Y., Xu M., Wu J., Cao H. Risk factors and outcomes of intraoperative atrial fibrillation in patients undergoing thoracoscopic anatomic lung surgery. Ann. Transl. Med. 2021; 9 (7): 543. DOI: 10.21037/atm-20-5035
  42. Phillips J., Porter E., Beaulieu-Jones B. Postoperative atrial fibrillation prophylaxis using a novel amiodarone order set. J. Thorac. Dis. 2020; 12 (6): 3110–24. DOI: 10.21037/jtd-20-180
  43. Balik M., Sander M., Trimmel H., Heinz G. Landiolol for managing post-operative atrial fibrillation. Eur. Heart J. Suppl. 2018; 20 (Suppl. A): A10–A14. DOI: 10.1093/eurheartj/sux036
  44. Nojiri T., Yamamoto H., Hamasaki T. A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial. Trials. 2017; 18 (1): 183. DOI: 10.1186/s13063-017-1928-1
  45. Nojiri T., Inoue M., Maeda H. Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery. Eur. J. Cardiothorac. Surg. 2013; 44 (1): 98–103. DOI: 10.1093/ejcts/ezs646
  46. Vesely D.L. Heart peptide hormones: adjunct and primary treatments of cancer. Anticancer. Res. 2016; 36 (11): 5693–700. DOI: 10.21873/anticanres.11152
  47. Serafino A., Moroni N., Psaila R. Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/b-catenin signaling. Biochim. Biophys. Acta. 2012; 1822 (6): 1004–18. DOI: 10.1016/j.bbadis.2012.02.016
  48. Nadir Y., Brenner B. Cancer and thrombosis – new insights. Rambam. Maimonides Med. J. 2018; 9 (4): 1–7. DOI: 10.5041/RMMJ.10349
****
  1. Bockeria L.A., Shengelia L.D. Treatment of atrial fibrillation. Part I. Long way to the gold standart. Annaly Aritmologii. 2014; 11 (2): 64–76 (in Russ.). DOI: 10.15275/ annaritmol.2014.2.1
  2. Bockeria L.A., Bazaev V.A., Filatov A.G., Melikulov A.Kh., Viskov R.V., Gritsay A.N. Lone atrial fibrillation. Annaly Aritmologii. 2006; 3 (2): 39–47 (in Russ.).
  3. Akamatsu K., Ito T., Ozeki M., Miyamura M., Sohmiya K., Hoshiga M. Left atrial spontaneous echo contrast occurring in patients with low CHADS2 or CHA2DS2-VASc scores. Cardiovasc. Ultrasound. 2020; 18 (1): 31. DOI: 10.1186/s12947-020-00213-2
  4. Wang C., Wu V., Tu H., Huang Y., Chen Sh., Chu P. et al. Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation. J. Thromb. Thrombolysis. 2021. DOI: 10.1007/s11239-021-02570-9
  5. Lateef N., Kapoor V., Ahsan M. Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. J. Community Hosp. Intern. Med. Perspect. 2020; 10 (2): 127–32. DOI: 10.1080/20009666.2020.1726571
  6. O’Neal W.T., Lakoski S.G., Qureshi W. Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study). Am. J. Cardiol. 2015; 115 (8): 1090–4. DOI: 10.1016/j.amjcard.2015.01.540
  7. Garcia S., Canoniero M., Sattiraju S. Atrial fibrillation after lung transplantation: incidence, predictors and long-term implications. J. Atr. Fibrillation. 2011; 4 (3): 363. DOI: 10.4022/jafib.363
  8. Hsu J., Huang C., Chuang S. Long term outcome of postoperative atrial fibrillation after cardiac surgery – a propensity score-matched cohort analysis. Front Cardiovasc. Med. 2021; 8: 650147. DOI: 10.3389/fcvm.2021.650147
  9. Gong J., Wang X., Liu Z. Risk factors and survival analysis of arrhythmia following lung cancer surgery: a retrospective study. J. Thorac. Dis. 2021; 13 (2): 847–60. DOI: 10.21037/jtd-20-2740
  10. Asnani A., Manning A., Mansour M., Ruskin J., Hochberg E., Ptaszek L. Management of atrial fibrillation in patients taking targeted cancer therapies. Cardiooncology. 2017; 3: 2. DOI: 10.1186/s40959-017-0021-y
  11. Kattelus H., KesКniemi Y., Huikuri H., Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). PLoS One. 2018; 13 (10): e0205454. DOI: 10.1371/journal.pone.0205454
  12. Tamura Y., Sawabata N., Susaki Y., Nakamura T., Taniguchi S. Effect of cardiac expansion on postsurgical pulmonary resection recovery. In Vivo. 2019; 33 (6): 1977–84. DOI: 10.21873/invivo.11693
  13. Kalra R., Parcha V., Patel N. Implications of atrial fibrillation among patients with atherosclerotic cardiovascular disease undergoing noncardiac surgery. Am. J. Cardiol. 2020; 125 (12): 1836–44. DOI: 10.1016/j.amjcard.2020.03.028
  14. Hung C.S., Chang C.H., Lin J.W., Ho Y.L., Chen M.F. The association between new onset atrial fibrillation and incident cancer – a nationwide cohort study. PLoS One. 2018; 13 (6): e0199901. DOI: 10.1371/journal.pone.0199901
  15. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 2020; 17 (8): 474–502. DOI: 10.1038/s41569-020- 0348-1
  16. Ren M., Yao Y., Yue X., Ning Y., Yang Y. Atrial cardiomyopathy and atrial fibrillation in cancer. Cardiol. Res. Pract. 2021; 2021: 6685951. DOI: 10.1155/2021/6685953
  17. Aboumsallem J.P., Moslehi J., de Boer R.A. Reverse cardio-oncology: cancer development in patients with cardiovascular disease. J. Am. Heart Assoc. 2020; 9 (2): e013754. DOI: 10.1161/JAHA.119.013754
  18. Zamorano J.L. Specific risk of atrial fibrillation and stroke in oncology patients. Eur. Heart J. 2016; 37 (36): 2747–8. DOI: 10.1093/eurheartj/ehw385
  19. Anderson J.L., Halperin J.L., Albert N.M. Management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013; 61 (18): 1935–44. DOI: 10.1016/j.jacc.2013.02.001
  20. Kaplan A., Joca H., Boyman L., Greiser M. Calcium signaling silencing in atrial fibrillation: implications for atrial sodium homeostasis. Int. J. Mol. Sci. 2021; 22 (19): 10513. DOI: 10.3390/ijms221910513
  21. Yang X., Li Y. Oxidative stress-mediated atherosclerosis: mechanisms and therapies. Front. Physiol. 2017; 8: 600. DOI: 10.3389/fphys.2017.00600
  22. Samman Tahhan A., Sandesara P.B., Hayek S.S. Association between oxidative stress and atrial fibrillation. Heart Rhythm. 2017; 14 (12): 1849–55. DOI: 10.1016/j.hrthm.2017.07.028
  23. Yang X., Li X., Yuan M. Anticancer therapy-induced atrial fibrillation: electrophysiology and related mechanisms. Front Pharmacol. 2018; 9: 1058. DOI: 10.3389/fphar.2018.01058
  24. Meessen J., Cardinale D., Ciceri F. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail. 2020; 7 (4): 1452–66. DOI: 10.1002/ehf2.12695
  25. Liu Y., Tan D., Shi L. Blueberry anthocyanins-enriched extracts attenuate cyclophosphamide-induced cardiac injury. PLOS One. 2015; 10 (7): e0127813. DOI: 10.1371/journal. pone.0127813
  26. Li N., Brundel B. Inflammasomes and proteostasis novel molecular mechanisms associated with atrial fibrillation. Circ. Res. 2020; 127 (1): 73–90. DOI: 10.1161/CIRCRESAHA.119.316364
  27. Yuan M., Zhang Z., Tse G., Feng X., Korantzopoulos P., Letsas K.P. et al. Association of cancer and the risk of developing atrial fibrillation: a systematic review and meta-analysis. Cardiol. Res. Pract. 2019; 2019: 8985273. DOI: 10.1155/2019/8985273
  28. January C.T., Wann L.S., Calkins H. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. Circulation. 2019; 140 (2): e125–e151. DOI: 10.1161/CIR.0000000000000665
  29. Citro R., Prota C., Resciniti E. Thrombotic risk in cancer patients: diagnosis and management of venous thromboembolism. J. Cardiovasc. Echogr. 2020; 30 (Suppl. 1): S38–S44. DOI: 10.4103/jcecho. jcecho_63_19
  30. Kim K., Lee Y.J., Kim T.H. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circ. J. 2018; 48 (5): 406–17. DOI: 10.4070/kcj.2017.0328
  31. Mosarla R.C., Vaduganathan M., Qamar A., Moslehi J., Piazza G., Giugliano R.P. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J. Am. Coll. Cardiol. 2019; 73 (11): 1336–49. DOI: 10.1016/j.jacc.2019.01.017
  32. Khan Y., Zaidi S.O., Razak B.S., Zaki M., Malik B.H. Use of new oral anticoagulants/direct oral anticoagulants in malignant patients. Cureus. 2020; 12 (2): e7007. DOI: 10.7759/cureus.7007
  33. Ma S., Mao Z., Wu Y. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell. Adh. Migr. 2020; 14 (1): 118–28. DOI: 10.1080/19336918.2020.1767489
  34. Horlocker T., Vandermeuelen E., Kopp S., Gogarten W., Leffert L., Benzon H. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg. Anesth. Pain. Med. 2018; 43 (3): 263–309. DOI: 10.1097/AAP.0000000000000763
  35. Chandrasekhar S., Fradley M.G. QT Interval prolongation associated with cytotoxic and targeted cancer therapeutics. Curr. Treat. Options. Oncol. 2019; 20 (7): 55. DOI: 10.1007/s11864-019-0657-y
  36. Bickford C., Agarwal R., Urbauer D., Durand J., Lenihan D. Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients. Am. J. Med. Sci. 2014; 347 (4): 277–81. DOI: 10.1097/MAJ.0b013e31828a7656
  37. Matta M., Gaita F., Anselmino M. Catheter ablation of atrial fibrillation in chronic heart failure: a contemporary review. J. Innov. Card. Rhythm. Manag. 2017; 8 (3): 2648–56. DOI: 10.19102/icrm.2017.080304
  38. Amar D., Zhang H., Tan K.S., Piening D., Rusch V.W., Jones D.R. A brain natriuretic peptide-based prediction model for atrial fibrillation after thoracic surgery: development and internal validation. J. Thorac. Cardiovasc. Surg. 2019; 157 (6): 2493–9.e1. DOI: 10.1016/j.jtcvs. 2019.01.075
  39. Fabiani I., Colombo A., Bacchiani G., Cipolla C., Cardinale D. Incidence, management, prevention and outcome of post-operative atrial fibrillation in thoracic surgical oncology. J. Clin. Med. 2019; 9 (1): 37. DOI: 10.3390/jcm9010037
  40. Semeraro G., Meroni C., Cipolla C., Cardinale D. Atrial fibrillation after lung cancer surgery: prediction, prevention and anticoagulation management. Cancers (Basel). 2021; 13 (16): 4012. DOI: 10.3390/cancers 13164012
  41. Tong C., Zhang Q., Liu Y., Xu M., Wu J., Cao H. Risk factors and outcomes of intraoperative atrial fibrillation in patients undergoing thoracoscopic anatomic lung surgery. Ann. Transl. Med. 2021; 9 (7): 543. DOI: 10.21037/atm-20-5035
  42. Phillips J., Porter E., Beaulieu-Jones B. Postoperative atrial fibrillation prophylaxis using a novel amiodarone order set. J. Thorac. Dis. 2020; 12 (6): 3110–24. DOI: 10.21037/jtd-20-180
  43. Balik M., Sander M., Trimmel H., Heinz G. Landiolol for managing post-operative atrial fibrillation. Eur. Heart J. Suppl. 2018; 20 (Suppl. A): A10–A14. DOI: 10.1093/eurheartj/sux036
  44. Nojiri T., Yamamoto H., Hamasaki T. A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial. Trials. 2017; 18 (1): 183. DOI: 10.1186/s13063-017-1928-1
  45. Nojiri T., Inoue M., Maeda H. Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery. Eur. J. Cardiothorac. Surg. 2013; 44 (1): 98–103. DOI: 10.1093/ejcts/ezs646
  46. Vesely D.L. Heart peptide hormones: adjunct and primary treatments of cancer. Anticancer. Res. 2016; 36 (11): 5693–700. DOI: 10.21873/anticanres.11152
  47. Serafino A., Moroni N., Psaila R. Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/b-catenin signaling. Biochim. Biophys. Acta. 2012; 1822 (6): 1004–18. DOI: 10.1016/j.bbadis.2012.02.016
  48. Nadir Y., Brenner B. Cancer and thrombosis – new insights. Rambam. Maimonides Med. J. 2018; 9 (4): 1–7. DOI: 10.5041/RMMJ.10349

Об авторах

  • Акилджонов Фирдавсджон Рустамджонович, аспирант; ORCID
  • Бузиашвили Юрий Иосифович, д-р мед. наук, профессор, академик РАН, заведующий клинико-диагностическим отделением; ORCID
  • Асымбекова Эльмира Уметовна, д-р мед. наук, вед. науч. сотр.; ORCID
  • Тугеева Эльвина Фаатовна, д-р мед. наук, ст. науч. сотр.; ORCID

 Если вы заметили опечатку, выделите текст и нажмите Alt+A